Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
Q D'Alessandris, N Montano, T Cenci… - Acta …, 2013 - search.ebscohost.com
Background: Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - academia.edu
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
N Montano, T Cenci, M Martini, L Lauretti… - Acta …, 2013 - search.proquest.com
Advances in comprehension of molecular biology of glioblastoma (GBM) have led to the
development of targeted therapies. The aim of the present study was to evaluate the efficacy …
development of targeted therapies. The aim of the present study was to evaluate the efficacy …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - infona.pl
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
N Montano, T Cenci, M Martini, L Lauretti… - ACTA …, 2012 - publicatt.unicatt.it
BACKGROUND: Advances in comprehension of molecular biology of glioblastoma (GBM)
have led to the development of targeted therapies. The aim of the present study was to …
have led to the development of targeted therapies. The aim of the present study was to …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
QG D'Alessandris, N Montano, T Cenci… - Acta …, 2012 - europepmc.org
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - researchgate.net
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
QG D'Alessandris, N Montano, T Cenci… - Acta …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …
[PDF][PDF] Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
QG D'Alessandris, N Montano, T Cenci, M Martini… - Acta …, 2013 - academia.edu
Background Advances in comprehension of molecular biology of glioblastoma (GBM) have
led to the development of targeted therapies. The aim of the present study was to evaluate …
led to the development of targeted therapies. The aim of the present study was to evaluate …